Antibiotic Resistance Market Size, Share & Trends Analysis Report By Pathogen (E. coli, K. pneumoniae, P. aeruginosa, S. aureus, A. baumannii, S. pneumoniae, H. influenzae, C. difficile, E. faecium), By Disease, By Technology, Region And Segment Forecasts, 2023-2031.

Report ID : 1244 | Published : 2023-07-22 | Pages: 185 | Format: PDF/EXCEL

The Antibiotic Resistance Market Size is valued at 10.15 Billion in 2022 and is predicted to reach 18.50 Billion by the year 2031 at a 7.0 % CAGR during the forecast period for 2023-2031.

Antibiotic Resistance Market

Antibiotics are antimicrobial chemicals that are used to treat bacterial infections. Strokes, sinus infections, urinary tract infections, ear infections, pneumonia, skin infections, and other diseases are all treated with them. The market has been supported by the high prevalence of antibiotic-resistance illnesses, and the rise of multi-drug resistant bacteria are expected to boost the market expansion in the next coming years. In addition, the accelerated need for novel therapies will further provide potential opportunities for the growth of the antibiotic resistance market over the upcoming years. The discovery of advanced prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to propel the market growth during the forecast period.

However, lack of investor concern in the research and development of resistance therapies, shortage of educated employees and strict safety rules are factors that may limit the growth of the target market during the forecast period. Advances in nutrition, medicine, and vaccination are factors that are likely to generate profitable revenue growth possibilities for participants in the worldwide Antibiotic Resistance market throughout the forecast period.

Market Segmentation:

The Antibiotic Resistance market is segmented based on pathogen type and applications. Based on pathogen type, the market is segmented as DRSP, DRC, CD, MRSA, DRNG, DRNTS, and Other Pathogen. Based on Technology market is segmented into antibiotics, Phage, Pep/Lys, Antibodies, Vaccine and others.

Based On Pathogen Type, The CD Segment Is Accounted As A Significant Contributor To The Antibiotic Resistance Market.

The CD category is expected to hold a major share in the global Antibiotic Resistance market in 2021. This is attributed to a number of cases in comparison to Gram-positive pathogens. They impose a high-cost burden as physicians are increasingly shifting towards novel antibiotics such as Allergan's Ayaz and Melinte Therapeutics' Vaporer. Also, these infections pose treatment challenges for physicians due to high resistance to current treatment alternatives.

Vaccine Segment Witnessed Growth At A Rapid Rate

The vaccine segment is projected to grow at a rapid rate in the global antibiotic resistance market owing to the increasing prevalence of viral infectious diseases are one of the major threats affecting a large population across the globe. The incidence of coronavirus infection has affected millions of individuals worldwide, which has created a significant demand for vaccines. There is an increase in demand for vaccines, especially in countries such as the US, Germany, the UK, China, and India. Also, Leading operating actors were involved in research and development for the creation of extremely effective preventative vaccines, which resulted in the introduction of several new medicines to the market.

In The Region, The North America Antibiotic Resistance Market Holds A Significant Revenue Share.

The North America Antibiotic Resistance market is expected to register the highest market share in terms of revenue soon. The regional market's expansion is being aided by several new medicine launches and significant treatment costs. North America and Europe are growing their use of the antibiotic resistance sector as a result of greater individual awareness regarding antibiotic resistance in this region. Antibiotic-resistant infections are on the rise, and healthcare-acquired conditions are on the increase in the United States.

In addition, Europe is projected to grow at a rapid rate in the global Antibiotic Resistance market. Greater engagement in terms of investment to combat resistance and implementing proper usage and stewardship standards for the use of antibiotics will boost market expansion over the upcoming years. The increased acceptance of antibiotic resistance and the increasing incidence of infectious diseases are some of the prior causes projected to drive the evolution of the antibiotic resistance marker.

Competitive Landscape

Some of The Key Players in the Antibiotic Resistance Market:

  • The Medicines Company
  • Melinta Therapeutics
  • Arsanis
  • Phage Technologies S.A
  • Westway Health
  • Tetraphase Pharmaceuticals
  • BioVersys GmbH
  • Nabriva Therapeutics.
  • Macrolide Pharmaceuticals
  • Nemesis Bioscience
  • C3J Therapeutics, Inc
  • EpiBiome
  • discuva
  • SmartPhage
  • AmpliPhi Biosciences
  • Pherecydes Pharma
  • Micreos
  • Procarta Biosystems
  • Lumavita
  • Madam Therapeutics
  • Priaxon
  • Biolytx Pharmaceuticals
  • AntibioTx
  • Xellia Pharmaceuticals
  • Paratek Pharmaceuticals
  • Synereca Pharmaceuticals
  • Allecra Therapeutics
  • Fixed Phage
  • Enanta Pharmaceuticals, Inc
  • Demuris
  • Prommune
  • Biosergen
  • Innovation Pharmaceuticals
  • Aviragen Therapeutics
  • Achillion Pharmaceuticals
  • ImmunNovative Developments, S.L.
  • Achaogen, Inc.
  • SelectX Pharmaceuticals, Inc.
  • TaiGen Biotechnology Co., Ltd
  • Theravance Biopharma
  • Abbvie
  • KYORIN Pharmaceutical Co., Ltd.
  • Iterum Therapeutics Limited
  • Forge Therapeutics
  • Alopexx Vaccine LLC
  • Integrated Biotherapeutics
  • Hennepin Life Sciences
  • Fedora Pharmaceuticals Inc
  • Contrafect Corporation
  • Basilea Pharmaceutica Ltd.
  • AiCuris
  • RedHill Biopharma
  • Redx Pharma Plc/ Redx Anti Infectives Ltd.
  • ABAC Therapeutics
  • Alaxia SAS
  • Antabio S.A.S
  • Auspherix Ltd
  • BioFilm Pharma
  • Centauri Therapeutics Ltd
  • Combioxin SA
  • Da Volterra
  • Debiopharm International SA
  • Deinobiotics/Deinove
  • Destiny Pharma plc
  • Eligo Bioscience
  • Helperby Therapeutics Ltd
  • Karveel Pharmaceuticals
  • MaaT Pharma
  • Motif BioSciences, Inc / Motif Bio PLC
  • Mutabilis SAS
  • Neem Biotech Ltd
  • Northern Antibiotics Oy (Ltd)
  • Nosopharm
  • NovaBiotics Ltd
  • Phico Therapeutics Ltd
  • Polyphor Ltd
  • QureTech Bio AB
  • SetLance Srl
  • Ultupharma AB
  • Vaxdyn
  • Vibiosphen
  • Bioaster
  • Vivexia
  • KBP Biosciences
  • Absynth Biologics
  • Spero Therapeutics
  • Merck
  • Symphogen
  • Warp Drive Bio
  • Johnson & Johnson (Janssen)
  • Pfizer
  • Allergan
  • Novartis
  • AstraZeneca
  • Cipla
  • DSM Sinochem Pharmaceuticals
  • Wockhardt Ltd.
  • VenatoRx Pharmaceuticals
  • MicuRx
  • Entasis Therapeutics
  • Merlion Pharmaceuticals
  • Aridis Pharmaceuticals Inc.
  • Other Prominent Players

The Antibiotic Resistance Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 10.15 Billion

Revenue Forecast In 2031

USD 18.50 Billion

Growth Rate CAGR

CAGR of 7.0 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Pathogen, By Disease, By Technology

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

The Medicines Company, Melinta Therapeutics, Arsanis, Phage Technologies S.A, Westway Health, Alaxia SAS, Antabio S.A.S, Auspherix Ltd, BioFilm Pharma, Centauri Therapeutics Ltd, Combioxin SA, Da Volterra, Debiopharm International SA, Deinove, Neem Biotech Ltd, Northern,, Antibiotics Oy (Ltd), Nosopharm, NovaBiotics Ltd, Phico Therapeutics Ltd, Polyphor Ltd, QureTech Bio AB,SetLance Srl, Ultupharma AB, Vaxdyn, Vibiosphen, Bioaster, Vivexia, KBP Biosciences, Absynth Biologics, Spero Therapeutics, Merck, Symphogen, Warp Drive Bio, Johnson & Johnson (Janssen), Pfizer, Allergan, Novartis, AstraZeneca, Cipla, DSM Sinochem Pharmaceuticals, Wockhardt Ltd., VenatoRx Pharmaceuticals, MicuRx, Entasis Therapeutics, Merlion Pharmaceuticals, Aridis Pharmaceuticals Inc, and others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

 

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary

Chapter 3. Global Antibiotic Resistance Market Snapshot

Chapter 4. Global Antibiotic Resistance Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers & Challenges
4.3. Trends
4.4. Porter’s Five Forces Analysis
4.5. Impact of COVID 19 Analysis
4.6. Clinical Trial/Pipeline Analysis 2020

Chapter 5. Market Segmentation 1: By Pathogen Estimates & Trend Analysis
5.1. By Pathogen & Market Share, 2020 & 2028
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Pathogen:
5.2.1.E. coli
5.2.2.K. pneumoniae
5.2.3.P. aeruginosa
5.2.4.S. aureus
5.2.5.A. baumannii
5.2.6.S. pneumoniae
5.2.7.H. influenzae
5.2.8.C. difficile
5.2.9.E. faecium
5.2.10. Other Pathogen

Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. By Technology & Market Share, 2020& 2028
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Technology:
6.2.1. Antibiotics
6.2.2. Phage
6.2.3. Pep/Lys
6.2.4. Antibodies
6.2.5. Vaccine
6.2.6. Other Technology

Chapter 7. Market Segmentation 2: By Disease Estimates & Trend Analysis
7.1. By Disease & Market Share, 2020& 2028
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Disease:
7.2.1. cUTI
7.2.1. CDI
7.2.1. ABSSSI
7.2.1. HABP
7.2.1. CABP
7.2.1. cIAI
7.2.1. BSI

Chapter 8. Antibiotic Resistance Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts By Pathogen, 2020-2028
8.1.2. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2020-2028
8.1.3. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2020-2028
8.1.3.1. U.S.
8.1.3.2. Canada

8.2. Europe
8.2.1. Europe Antibiotic Resistance Market Revenue (US$ Million) By Pathogen, 2020-2028
8.2.2. Europe Antibiotic Resistance Market Revenue (US$ Million) By Technology, 2020-2028
8.2.3. Europe Antibiotic Resistance Market Revenue (US$ Million) by Country, 2020-2028
8.2.3.1. Germany
8.2.3.2. France
8.2.3.3. Italy
8.2.3.4. Spain
8.2.3.5. UK
8.2.3.6. Romania
8.2.3.8. Netherland
8.2.3.8. Belgium
8.2.3.9. Rest of Europe

8.3. Asia Pacific
8.3.1. Asia Pacific Antibiotic Resistance Market revenue (US$ Million) By Pathogen, 2020-2028
8.3.2. Asia Pacific Antibiotic Resistance Market revenue (US$ Million) By Technology, 2020-2028
8.3.3. Asia Pacific Antibiotic Resistance Market revenue (US$ Million) by Country, 2020-2028
8.3.3.1. China
8.3.3.2. India
8.3.3.3. Japan
8.3.3.4. Australia
8.3.3.5. Rest of Asia Pacific

8.4. Latin America
8.4.1. Latin America Antibiotic Resistance Market revenue (US$ Million) By Pathogen, (US$ Million)
8.4.2. Latin America Antibiotic Resistance Market revenue (US$ Million) By Technology, (US$ Million)
8.4.3. Latin America Antibiotic Resistance Market revenue (US$ Million) by Country, (US$ Million) 2020-2028
8.4.3.1. Brazil
8.4.3.2. Rest of Latin America

8.5. Middle East & Africa
8.5.1. Middle East & Africa Antibiotic Resistance Market revenue (US$ Million) By Pathogen, (US$ Million)
8.5.2. Middle East & Africa Antibiotic Resistance Market revenue (US$ Million) By Technology, (US$ Million)
8.5.3. Middle East & Africa Antibiotic Resistance Market revenue (US$ Million) by Country, (US$ Million) 2020-2028
8.5.3.1. GCC Countries
8.5.3.2. Rest of Middle East & Africa

Chapter 8. Competitive Landscape
9.1. Company Profiles
9.1.1. The Medicines Company
9.1.2. Melinta Therapeutics
9.1.3. Arsanis
9.1.4. Phage Technologies S.A
9.1.5. Westway Health
9.1.6. Tetraphase Pharmaceuticals
9.1.7. BioVersys GmbH
9.1.8. Nabriva Therapeutics.
9.1.9. Macrolide Pharmaceuticals
9.1.10. Nemesis Bioscience
9.1.11. C3J Therapeutics, Inc
9.1.12. EpiBiome
9.1.13. discuva
9.1.14. SmartPhage
9.1.15. AmpliPhi Biosciences
9.1.16. Pherecydes Pharma
9.1.18. Micreos
9.1.18. Procarta Biosystems
9.1.19. Lumavita
9.1.20. Madam Therapeutics
9.1.21. Priaxon
9.1.22. Biolytx Pharmaceuticals
9.1.23. AntibioTx
9.1.24. Xellia Pharmaceuticals
9.1.25. Paratek Pharmaceuticals
9.1.26. Synereca Pharmaceuticals
9.1.28. Allecra Therapeutics
9.1.28. Fixed Phage
9.1.29. Enanta Pharmaceuticals, Inc
9.1.30. Demuris
9.1.31. Prommune
9.1.32. Biosergen
9.1.33. Innovation Pharmaceuticals
9.1.34. Aviragen Therapeutics
9.1.35. Achillion Pharmaceuticals
9.1.36. ImmunNovative Developments, S.L.
9.1.38. Achaogen, Inc.
9.1.38. SelectX Pharmaceuticals, Inc.
9.1.39. TaiGen Biotechnology Co., Ltd
9.1.40. Theravance Biopharma
9.1.41. Abbvie
9.1.42. KYORIN Pharmaceutical Co., Ltd.
9.1.43. Iterum Therapeutics Limited
9.1.44. Forge Therapeutics
9.1.45. Alopexx Vaccine LLC
9.1.46. Integrated Biotherapeutics
9.1.48. Hennepin Life Sciences
9.1.48. Fedora Pharmaceuticals Inc
9.1.49. Contrafect Corporation
9.1.50. Basilea Pharmaceutica Ltd.
9.1.51. AiCuris
9.1.52. RedHill Biopharma
9.1.53. Redx Pharma Plc/ Redx Anti Infectives Ltd.
9.1.54. ABAC Therapeutics
9.1.55. Alaxia SAS
9.1.56. Antabio S.A.S
9.1.58. Auspherix Ltd
9.1.58. BioFilm Pharma
9.1.59. Centauri Therapeutics Ltd
9.1.60. Combioxin SA
9.1.61. Da Volterra
9.1.62. Debiopharm International SA
9.1.63. Deinobiotics/Deinove
9.1.64. Destiny Pharma plc
9.1.65. Eligo Bioscience
9.1.66. Helperby Therapeutics Ltd
9.1.68. Karveel Pharmaceuticals
9.1.68. MaaT Pharma
9.1.69. Motif BioSciences, Inc / Motif Bio PLC
9.1.70. Mutabilis SAS
9.1.71. Neem Biotech Ltd
9.1.72. Northern Antibiotics Oy (Ltd)
9.1.73. Nosopharm
9.1.74. NovaBiotics Ltd
9.1.75. Phico Therapeutics Ltd
9.1.76. Polyphor Ltd
9.1.78. QureTech Bio AB
9.1.78. SetLance Srl
9.1.79. Ultupharma AB
9.1.80. Vaxdyn
9.1.81. Vibiosphen
9.1.82. Bioaster
9.1.83. Vivexia
9.1.84. KBP Biosciences
9.1.85. Absynth Biologics
9.1.86. Spero Therapeutics
9.1.88. Merck
9.1.88. Symphogen
9.1.89. Warp Drive Bio
9.1.90. Johnson & Johnson (Janssen)
9.1.91. Pfizer
9.1.92. Allergan
9.1.93. Novartis
9.1.94. AstraZeneca
9.1.95. Cipla
9.1.96. DSM Sinochem Pharmaceuticals
9.1.98. Wockhardt Ltd.
9.1.98. VenatoRx Pharmaceuticals
9.1.99. MicuRx
9.1.100. Entasis Therapeutics
9.1.101. Merlion Pharmaceuticals
9.1.102. Aridis Pharmaceuticals Inc
9.1.103. Other Prominent Players

 

Segmentation of Antibiotic Resistance Market-

By Pathogen

  • E. coli
  • K. pneumoniae
  • P. aeruginosa
  • S. aureus
  • A. baumannii
  • S. pneumoniae
  • H. influenzae
  • C. difficile
  • E. faecium

Antibiotic Resistance Market

By Disease

  • cUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI

By Technology

  • Antibiotics
  • Phage
  • Pep/Lys
  • Antibodies
  • Vaccine
  • Other Technology"

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Antibiotic Resistance Market Size?

The Antibiotic Resistance Market is expected to grow at a 7.0 % CAGR during the forecast period for 2023-2031.

The Medicines Company, Melinta Therapeutics, Arsanis, Phage Technologies S.A, Westway Health, Alaxia SAS, Antabio S.A.S, Auspherix Ltd, BioFilm Pharma

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..